Effects of Nitric Oxide for Inhalation in Myocardial Infarction Size (NOMI)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01398384 |
Recruitment Status
:
Completed
First Posted
: July 20, 2011
Last Update Posted
: May 21, 2014
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Acute Myocardial Infarction | Drug: Nitric Oxide Drug: MI size at 48-72 hours | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 250 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | The Effects of Nitric Oxide for Inhalation on Myocardial Infarction Size |
Study Start Date : | October 2010 |
Actual Primary Completion Date : | May 2014 |
Actual Study Completion Date : | May 2014 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Nitric Oxide
nitric oxide for inhalation
|
Drug: Nitric Oxide
MI size at 48-72 hours
Other Name: vasoKINOX 450
|
Placebo Comparator: Placebo
inhalation gas
|
Drug: MI size at 48-72 hours
Placebo gas
|
- Myocardial infarction size as a fraction of left ventricular size [ Time Frame: 48-72 hours ]Myocardial infarction size as a fraction of left ventricular size at 48-72 hours in patients presenting with an ST segment elevation MI who undergo successful percutaneous coronary intervention.
- MI size, extent and transmurality of microvascular obstruction [ Time Frame: 48-72 hours ]MI size, extent and transmurality of microvascular obstruction measured by MRI
- MI size normalized to area at risk [ Time Frame: 48-72 hours ]
- Myocardial perfusion at coronary angiography at the completion of PCI (corrected TIMI frame count and myocardial blush grade). [ Time Frame: at completion of PCI, as expected 1 day ]
- Transmurality of infarct (as average percent wall thickness in all segments showing delayed enhancement). [ Time Frame: at 48 - 72 hours and 4 months ]
- Myocardial perfusion(MRI). [ Time Frame: at 48-72 hours and 4 months ]
- Global and regional left ventricular function and left ventricular mass at 48 - 72hours and 4 months after MI and the change in global LV function and mass between 48-72 hours and 4 months. MI size as a fraction of LV size at 4 months after MI. [ Time Frame: 48-72 hours and 4 months ]
- Resolution of ST segment elevation (serial ECGs) as indicated by the decrease in the total ST elevation (in mV) at 4 hours compared with that observed at enrollment. [ Time Frame: at 4 hours ]
- Troponin T levels and CPK-MB area under the curve at 48 hours. [ Time Frame: 48 hours ]
- Change in adverse remodeling parameters (compared with 48-72 hours):changes in LV end-diastolic volume, end-systolic volume, end-diastolic myocardial wall thickness in infarct, peri-infarct and remote areas and in sphericity index. [ Time Frame: 4 months ]Change in adverse remodeling parameters (compared with 48-72 hours):changes in LV end-diastolic volume, end-systolic volume, end-diastolic myocardial wall thickness in infarct, peri-infarct and remote areas and in sphericity index at end-diastole and end-systole.
- Death, nonfatal recurrent MI, recurrent ischemia necessitating re-hospitalization, PCI, or surgical revascularization, and stroke (i.e. combined CV endpoint) at 4 months. Enzyme leak during subsequent scheduled PCI will not be considered new ischemia/MI. [ Time Frame: 4 months ]
- Assess the safety of inhaled NO for this use as determined by reported adverse events (including bleeding and laboratory changes). [ Time Frame: during treatment gas period, an average of 6 hours ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Acute myocardial infarction (defined as an episode of chest pain or related symptom lasting greater than 2 hours but less than 12 hours and electrocardiographic evidence of ST elevation (measured as 0.08 seconds after the J point; sum greater or equal to 0.6 mV in leads I, II, III, AVL, AVF, V1-V6).
- No evidence of congestive heart failure (no S3 or evidence of pulmonary edema) and normal oxygen saturation on ≤ 2L oxygen by NC.
- All patients must undergo successful percutaneous coronary intervention for TIMI 0 or 1 coronary flow with resulting TIMI 2 or 3 (residual stenosis less than 30% if stented and less than 50% if opened by balloon angioplasty).
- Age > 18 years.
- Signed EC approved informed consent.
Exclusion Criteria:
- Prior myocardial infarction (as determined by patient history and/or ECG), cardiac surgery, or severe pericardial, congenital, cardiomyopathic or valvular heart disease.
- Requirement for urgent cardiac surgery.
- Previous CABG or PCI.
- Left bundle branch block.
- Unable to tolerate magnetic resonance imaging (including disallowed metallic implants or BMI > 35) or unable to tolerate gadolinium contrast media, including patients with calculated creatinine clearance less than 60 ml/min/1.73 m2 BSA.
- Active or recent hemorrhage requiring an invasive procedure for evaluation or transfusion within 6 weeks prior to presentation or hemorrhagic stroke within the 6 weeks prior to presentation.
- Known or suspected aortic dissection.
- Prior history of pulmonary disease requiring chronic oxygen therapy.
- Pregnancy, lactating and woman of childbearing potential.
- Use of investigational drugs or device within the 30 days prior to enrollment to the study. Investigational uses of approved therapies will be allowed.
- Medical problem likely to preclude completion of the study.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01398384
Belgium | |
Jessa Hospital | |
Hasselt, Belgium | |
UZ Leuven | |
Leuven, Belgium, 3000 | |
Hungary | |
Semmelweis University Heart Center | |
Budapest, Hungary, 1122 | |
Poland | |
John Paul II Hospital | |
Krakow, Poland, 31-202 |
Principal Investigator: | Stefan Janssens, Prof Dr | UZ Leuven | |
Principal Investigator: | Frans Van de Werf, Prof Dr | UZ Leuven |
Additional Information:
Responsible Party: | Universitaire Ziekenhuizen Leuven |
ClinicalTrials.gov Identifier: | NCT01398384 History of Changes |
Other Study ID Numbers: |
LCC2010.01 |
First Posted: | July 20, 2011 Key Record Dates |
Last Update Posted: | May 21, 2014 |
Last Verified: | May 2014 |
Keywords provided by Universitaire Ziekenhuizen Leuven:
ST Elevation MI STEMI |
Additional relevant MeSH terms:
Infarction Myocardial Infarction Ischemia Pathologic Processes Necrosis Myocardial Ischemia Heart Diseases Cardiovascular Diseases Vascular Diseases Nitric Oxide Bronchodilator Agents Autonomic Agents |
Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Asthmatic Agents Respiratory System Agents Free Radical Scavengers Antioxidants Molecular Mechanisms of Pharmacological Action Neurotransmitter Agents Endothelium-Dependent Relaxing Factors Vasodilator Agents Gasotransmitters Protective Agents |